4598 Delta-Fly Pharma
- 677
- -38-5.31%
Delta-Fly Pharma News
Express News | [Large Shareholding Report] JP Morgan Securities reported a 5.13% Shareholding in Delta-Fly Pharma (4598.JP).
Express News | [Change Report] Macquarie Silver in Australia reported a reduction in its shareholding of Delta-Fly Pharma (4598.JP) to 9.73%.
The Tokyo Stock Exchange Growth Market Index has retreated, reflecting a wait-and-see mood similar to the main market.
Tokyo Growth Market Index 817.32 -6.99 / Volume 0.2 billion 31.3 million shares / Trading value 153.5 billion yen Tokyo Growth Market 250 Index 638.27 -6.54 / Volume 0.1 billion 12.95 million shares / Trading value 118.7 billion yen In today's growth market, both the Tokyo Growth Market Index and the Tokyo Growth Market 250 Index fell. The number of rising stocks was 167, the number of declining stocks was 398, and unchanged was 33. In the USA market on the 13th, the Dow Inc average fell by 86.06 dollars to 43,828.
Stocks that moved the previous day part 2: Metaplanet, Pluszero, eWeLL ETC.
Stock name <code> Closing price on the 12th ⇒ Change from the previous day Synchro Food <3963> 382 -35 Announced public offering and sale, leading to concerns about dilution and supply-demand in the short term. Pharma Foods <2929> 915 -43 Significant increase in profits in the first quarter, but the surprises are few. Tsuburaya Productions HD <2767> 1881 -32 High level of margin purchases is still noted during the decline. Fixstars <3687> 1850 -84 Related to quantum computers, saw a significant increase on the 11th.
Volume change rate ranking (10:00) ~ DELTA-P, Daiwa Communications, etc. are ranked
In the ranking of Volume change rates, comparing the average Volume over the last 5 days with the Volume on the day of delivery allows us to understand trends in stock selection and the interests of market participants. ■ Top Volume Change Rates [As of December 12, 10:32] (Comparative with average Volume over the last 5 days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <4598> DELTA-P 4089700117118.56 358.14% 0.0428% <711
Volume change rate ranking (9:00) ~ Pharma Foods, GA TECH, etc. are ranked
* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [as of 12/12 9:32] (Last 5 Day Average Volume Comparison) Stock Code Stock Name Volume 5 Day Average Volume Volume Change Rate ＜4598＞DELTA-P 2430400107185.08333.62% 0.0591% ＜7116
Kaiomu, DELTA-P and others.
＜1431＞Completion of stock buyback by Live Work. ＜4583＞Joint research contract concluded with Aiome. ＜4523＞Mass exercise of DELTA-P's 8th subscription rights (with exercise price adjustment clause) starts on the 11th, number of shares to be delivered, 0.45 million shares. ＜6180＞Completion of stock buyback by GMO Broadcasting. ＜6558＞Cookbiz downward revision of this fiscal year's operating profit forecast to 0.091 billion yen from 0.351 billion yen. ＜7707＞PSS joint venture with FerroTec Holdings ＜6890＞.
Emerging Markets stock digest: BTM has significantly declined for five consecutive days, while AViC has reached its year-to-date high.
A significant decline. The operating profit Financial Estimates for the fiscal year ending July 2025 have been revised upwards from the previous estimate of 0.175 billion to -0.415 billion yen to 0.31 billion to -0.425 billion yen (previous year's actual result was 0.263 billion yen).
DELTA-P --- The stock is at a high buy indication, with approval for tolerability in clinical trials targeted at acute myeloid leukemia, confirming complete remission.
The stock has a buy preference at the limit. It was announced after the close of trading on the 9th that the data evaluation committee (DMC) approved the tolerability of the first three cases in the clinical phase 1/2 trial of "DFP-10917," a development product being advanced in the USA for patients with acute myeloid leukemia who were ineffective or relapsed after prior treatment (first-line therapy), in combination with VEN. The number of bone marrow cells in peripheral blood for all three cases reached zero within four weeks of starting treatment, and subsequent bone marrow examinations showed...
Stocks hitting the upper or lower price limit in the afternoon session.
■ Price increase limit <1730> Asou Foam Concrete <2776> Shinto Holdings <3961> Silver Egg Technology <4073> G.C. Planning <4598> Delta-Fly Pharma <4937> Waqoo <6180> GMO Broadcasting <7732> Topcon <9165> Qualtech ■ Price decrease limit * Includes temporary price highs and lows (indicative prices).
Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 With Venetoclax
Stocks that moved the day before part 2: Mitsubishi Logistics Next, Discharge Precision, Discharge Precision, etc.
Stock name <code> Closing Price on the 6th ⇒ Compared to the previous day Sumitomo Electric Industries <5802> 2931.0 -121.0 Mizuho Securities has downgraded its investment determination. Japan Steel Works <5631> 6232 -280, a situation has developed where the sense of reaching the upper limits is expanding temporarily. Fujikura <5803> 6122 -253, a trend is emerging where profit-taking sells are directed in the high price range. FP Partners <7388> 2285 -66, the Financial Services Agency has decided to conduct additional investigations regarding the company’s trades with life insurance companies. Peptidream <4587> 2810 -8310, the high price in October.
Stocks that moved the previous day part 2. Aiz, Eurasia Travel Agency, Japan Oxygen HD, etc.
Stock name <code> 5-day closing price ⇒ compared to the previous day China Electric Power <9504> 902.0 -34.7 Major electrical utilities stocks are generally under a sell bias. Japan Oxygen HD <4091> 4332 -135 morgan stanley MUFG Securities has lowered its target stock price. Rakuten Bank <5838> 4110 -126 The speculation about the Bank of Japan postponing interest rate hikes in December is growing stronger. Kasumigaseki Capital <3498> 12390 -400 Approaching the 25-day moving average level, selling on the rebound may be dominant. Tohoku Electric Power <9506>
Emerging markets stock digest: KAIOMU sharply rebounds, True Data hits limit up.
＜5027＞ AnyMind 1129 -2 is in a consolidation phase. After the close of trading on the 4th, it started to rebound following the announcement of strengthened collaboration with TikTok and the launch of new advertising features in Thailand, but it has now entered a consolidation phase. Due to the development of new features that strengthen the collaboration between the influencer marketing platform 'AnyTag' and the short video platform 'TikTok', it has begun to be offered in Thailand through 'AnyTag'.
Hot stocks digest (morning session): Osaka Soda, Keeper Giken, True Data, etc.
Musashi Seimitsu <7220>: ¥3935 (+¥65) significantly extended. Oracle corp announced that they have adopted their HSC for the company's cloud computing cluster, leading to strong movement the previous day. The HSC Innovation Forum was held yesterday, further fueling today's upward momentum. Customers noted that no alternative material suitable for their HSC as a power solution could be found, renewing expectations for medium to long-term performance contribution.
Volume change rate ranking (9:00 hour) - DELTA-P, Osaka Soda, etc. ranked in.
In the volume change rate ranking, you can understand the interest of market participants such as trends in selection by comparing the average volume of the recent 5 days with the volume on the delivery day.■ Volume change rate top [As of 9:32 on December 5] (Comparison of average volume of the last 5 days) Code Name Volume 5-day Average Volume Volume Change Rate Price Change Rate＜1478＞iS High Dividend Concept 33802 107 185.08 148.03% 0.0013%＜7760＞IMV4
DELTA-P has ranked in, announcing the test design for the next test of DFP-17729.
DELTA-P <4598> is ranked (as of 9:32 AM). It shows a significant rebound. After the close of the previous day's trade, it was announced that face-to-face advice was conducted with the National Institute of Health Sciences and Environment (PMDA) regarding the next steps in the DFP-17729 trial. The content involves a Phase 2/3 clinical trial aimed at patients after third-line treatment for pancreatic cancer, and the trial design has been approved to compare the combination group of DFP-17729 and TS-1 with the TS-1 monotherapy group.
DELTA-P--- rebound, announcing the development status of DFP-17729.
There was a rebound. After the close of trading on the 4th, the development status of DFP-17729 was announced, which was well received. Meetings for advice were held with the Pharmaceuticals and Medical Devices Agency (PMDA) regarding the next steps in testing, and the design for a Phase 2/3 clinical trial aimed at patients after the third-line treatment for pancreatic cancer was approved, comparing the combination group of DFP-17729 and TS-1 with the TS-1 alone group. TS-1 was developed in japan by Taiho Pharmaceutical and was released in 1999.
Strong performance, supported by rising U.S. stocks [emerging markets individual stock global strategy]
[Emerging Markets Individual Stock Global Strategy] Today's emerging markets are expected to show a steady performance. In the U.S. stock market on the 4th, the Dow Jones Industrial Average rose by 308.51 points (+0.69%) to 45,014.04, rebounding for the first time in three days. This was supported by the confirmation of robust job growth in the private sector’s November ADP employment statistics and a decline in long-term interest rates, which bolstered stock prices. Additionally, towards the end of the session, Federal Reserve Chairman Powell expressed an optimistic outlook for the economy in an interview, and the Federal Reserve released...
Kaiom, Cybadein - other recommendations.
Acquired land for the development of the Paloma self-storage facility (land in Yokohama City, Kanagawa Prefecture) <4583> Partnership with Fujifilm Wako Pure Chemical Corporation, engaged in the manufacture and sale of reagents, chemical products, and clinical laboratory tests <4598> Regarding the development status of DELTA-PDFP-17729, a comparative study will be conducted targeting patients after the third line of treatment for pancreatic cancer, comparing the combination group of DFP-17729 and TS-1 with the TS-1 alone group.
No Data